SEC Form 4 · accession 0001214659-18-004614
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Christensen
Officer — SVP, Chief Scientific Officer
Period of report
Jun 26, 2018
Accepted (ET)
Jun 28, 2018 · 7:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 26, 2018 | M | 5,208 | $5.40 | A | 8,085 | D | |
| Common StockF2 | Jun 26, 2018 | S | 4,058 | $48.6218 | D | 4,027 | D | |
| Common StockF3,F6 | Jun 26, 2018 | S | 1,150 | $49.2674 | D | 3,394 | D | |
| Common Stock | Jun 27, 2018 | M | 4,999 | $5.50 | A | 8,393 | D | |
| Common StockF4 | Jun 27, 2018 | S | 4,234 | $49.4252 | D | 4,159 | D | |
| Common StockF5 | Jun 27, 2018 | S | 736 | $50.1499 | D | 3,423 | D | |
| Common Stock | Jun 27, 2018 | S | 29 | $51.325 | D | 3,394 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F7 | $5.40 | Jun 26, 2018 | M | 5,208 | D | — | Jan 25, 2027 | Common Stock | 5,208 | 32,292 | D |
| Employee Stock Option (Right to Buy)F7 | $5.50 | Jun 27, 2018 | M | 4,999 | D | — | Oct 26, 2026 | Common Stock | 4,999 | 17,502 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $48.05 to $49.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $49.05 to $49.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $48.90 to $49.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $49.90 to $50.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6Includes 517 shares acquired under the ESPP Purchase on 05/31/18.
- F71/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of theshares subject to the Option shall vest each month thereafter until fully vested.